Skip to content

Molecular Data Inc.: financial reference

Explore Molecular Data Inc. financial histories from SEC filings, with original units, reporting periods, filing dates and downloadable source data.

Filing record ends 2021-05-17

The latest filing in this captured record is a 20-F filed 2021-05-17. No later filing is in the SEC companyfacts record captured on 2026-09-22. Molecular Data Inc. may have stopped filing, merged, or changed its reporting entity; nothing on this page describes its current status. Values are as reported at the time.

Reported financial histories

Choose a measure to inspect its definition, complete selected history and filing provenance. Each row shows the latest period available for that selected concept and original unit. Separate currencies and reporting intervals remain separate rows. Coverage dates can differ between concepts. A recent capture does not imply recent accounting coverage; these amounts are not prices.

Latest periods by selected concept and original unit
MeasurePeriod startPeriod endValueUnitFiled
Total assets-2020-12-31684,821,000CNY2021-05-17
Total assets-2020-12-31104,952,000USD2021-05-17
Total liabilities-2020-12-31712,658,000CNY2021-05-17
Total liabilities-2020-12-31109,219,000USD2021-05-17
Stockholders equity-2020-12-31-27,928,000CNY2021-05-17
Stockholders equity-2020-12-31-4,281,000USD2021-05-17
Cash and cash equivalents-2020-12-3111,311,000CNY2021-05-17
Cash and cash equivalents-2020-12-311,733,000USD2021-05-17
Net income or loss2020-01-012020-12-31-327,997,000CNY2021-05-17
Net income or loss2020-01-012020-12-31-50,268,000USD2021-05-17
Operating cash flow2020-01-012020-12-31-234,048,000CNY2021-05-17
Operating cash flow2020-01-012020-12-31-35,870,000USD2021-05-17
Capital expenditure payments2019-01-012019-12-31853,000CNY2020-06-30
Capital expenditure payments2019-01-012019-12-31123,000USD2020-06-30
Contract revenue excluding tax2020-01-012020-12-317,596,412,000CNY2021-05-17
Contract revenue excluding tax2020-01-012020-12-311,164,201,000USD2021-05-17
Financing cash flow2020-01-012020-12-31529,143,000CNY2021-05-17
Financing cash flow2020-01-012020-12-3181,095,000USD2021-05-17
Investing cash flow2020-01-012020-12-31-320,308,000CNY2021-05-17
Investing cash flow2020-01-012020-12-31-49,089,000USD2021-05-17
Retained earnings or deficit-2020-12-31-1,081,914,000CNY2021-05-17
Retained earnings or deficit-2020-12-31-165,811,000USD2021-05-17
Basic weighted-average shares2020-01-012020-12-31348,160,637shares2021-05-17
Diluted weighted-average shares2020-01-012020-12-31376,052,756shares2021-05-17
Basic earnings per share2020-01-012020-12-31-0.94CNY/shares2021-05-17
Basic earnings per share2020-01-012020-12-31-0.14USD/shares2021-05-17
Diluted earnings per share2020-01-012020-12-31-0.87CNY/shares2021-05-17
Diluted earnings per share2020-01-012020-12-31-0.13USD/shares2021-05-17
Income tax expense or benefit2020-01-012020-12-312,458,000CNY2021-05-17
Income tax expense or benefit2020-01-012020-12-31377,000USD2021-05-17
Net property, plant and equipment-2020-12-31725,000CNY2021-05-17
Net property, plant and equipment-2020-12-31111,000USD2021-05-17
Share-based compensation expense2020-01-012020-12-3144,526,000CNY2021-05-17
Share-based compensation expense2020-01-012020-12-316,824,000USD2021-05-17
Operating income or loss2020-01-012020-12-31-331,557,000CNY2021-05-17
Operating income or loss2020-01-012020-12-31-50,813,000USD2021-05-17
Current assets-2020-12-31663,186,000CNY2021-05-17
Current assets-2020-12-31101,637,000USD2021-05-17
Interest expense2020-01-012020-12-3110,727,000CNY2021-05-17
Interest expense2020-01-012020-12-311,644,000USD2021-05-17
Current liabilities-2020-12-31692,606,000CNY2021-05-17
Current liabilities-2020-12-31106,146,000USD2021-05-17
Net finite-lived intangible assets-2020-12-31536,000CNY2021-05-17
Net finite-lived intangible assets-2020-12-3182,000USD2021-05-17
Net current accounts receivable-2020-12-315,963,000CNY2021-05-17
Net current accounts receivable-2020-12-31914,000USD2021-05-17
Operating expenses2020-01-012020-12-31321,358,000CNY2021-05-17
Operating expenses2020-01-012020-12-3149,250,000USD2021-05-17
Net inventory-2020-12-312,821,000CNY2021-05-17
Net inventory-2020-12-31432,000USD2021-05-17
Gross profit2020-01-012020-12-31-10,199,000CNY2021-05-17
Gross profit2020-01-012020-12-31-1,563,000USD2021-05-17
Research and development expense2020-01-012020-12-3135,215,000CNY2021-05-17
Research and development expense2020-01-012020-12-315,397,000USD2021-05-17
Cash including restricted cash-2020-12-3111,588,000CNY2021-05-17
Cash including restricted cash-2020-12-311,775,000USD2021-05-17
Additional paid-in capital-2020-12-311,075,064,000CNY2021-05-17
Additional paid-in capital-2020-12-31164,761,000USD2021-05-17
Total equity including noncontrolling interests-2020-12-31-27,879,000CNY2021-05-17
Total equity including noncontrolling interests-2020-12-31-4,273,000USD2021-05-17
Gross property, plant and equipment-2020-12-314,934,000CNY2021-05-17
Gross property, plant and equipment-2020-12-31756,000USD2021-05-17
Accumulated depreciation on property, plant and equipment-2020-12-314,209,000CNY2021-05-17
Accumulated depreciation on property, plant and equipment-2020-12-31645,000USD2021-05-17
Net intangible assets excluding goodwill-2020-12-31536,000CNY2021-05-17
Net intangible assets excluding goodwill-2020-12-3182,000USD2021-05-17
Accrued current liabilities-2020-12-3116,171,000CNY2021-05-17
Accrued current liabilities-2020-12-312,478,000USD2021-05-17
Prepaid expenses and other current assets-2020-12-31229,046,000CNY2021-05-17
Prepaid expenses and other current assets-2020-12-3135,103,000USD2021-05-17
Current contract liabilities-2020-12-3181,636,000CNY2021-05-17
Current contract liabilities-2020-12-3112,511,000USD2021-05-17
Profit or loss including noncontrolling interests2020-01-012020-12-31-328,038,000CNY2021-05-17
Profit or loss including noncontrolling interests2020-01-012020-12-31-50,274,000USD2021-05-17
Comprehensive income or loss2020-01-012020-12-31-307,121,000CNY2021-05-17
Comprehensive income or loss2020-01-012020-12-31-47,069,000USD2021-05-17
Net income available to common stockholders2020-01-012020-12-31-327,997,000CNY2021-05-17
Net income available to common stockholders2020-01-012020-12-31-50,268,000USD2021-05-17
General and administrative expense2020-01-012020-12-31210,401,000CNY2021-05-17
General and administrative expense2020-01-012020-12-3132,245,000USD2021-05-17
Depreciation expense2020-01-012020-12-31584,000CNY2021-05-17
Depreciation expense2020-01-012020-12-3190,000USD2021-05-17
Amortization of intangible assets2020-01-012020-12-311,140,000CNY2021-05-17
Amortization of intangible assets2020-01-012020-12-31175,000USD2021-05-17
Interest paid, net2019-01-012019-12-314,428,000CNY2020-06-30
Interest paid, net2019-01-012019-12-31636,000USD2020-06-30
Change in accounts receivable2020-01-012020-12-31-13,155,000CNY2021-05-17
Change in accounts receivable2020-01-012020-12-31-2,016,000USD2021-05-17
Change in inventories2020-01-012020-12-31-1,530,000CNY2021-05-17
Change in inventories2020-01-012020-12-31-234,000USD2021-05-17

Filings

2 Molecular Data filings with published measures: what each annual or quarterly report tagged, with the periods it covered, as reported in that filing. The histories above show the latest-filed value per period.

Inspect the source

Entity
Molecular Data Inc. / CIK 0001758736
Captured
SEC response SHA-256
f946338599cd1510d55df42eb95733ac362266282fe1e397fbd5aeb3e483a5c8

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001758736.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))